ATRNL1

Across TCGA pan-cancer cohorts, ATRNL1 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated ATRNL1 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher ATRNL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ATRNL1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

READ, ESCA, and UCEC are the cancer types where ATRNL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	II,III,IV	0.111	0.919	<.001	39	view →
ESCA	OS	Median	All	0.205	0.716	<.001	30	view →
UCEC	DFS	Median	II,III,IV	0.901	0.300	.008	28	view →
BLCA	DFS	Median	IV	0.160	0.482	.010	22	view →
LUSC	DFS	Median	III,IV	0.079	0.751	.024	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	IV	0.153	0.714	.012	6	view →
COAD	DFS	Median	All	1.000	0.460	.033	2	view →
BRCA	DFS	Median	All	0.745	0.949	.048	2	view →
SKCM	DFS	Median	IV	1.000	0.201	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

ATRNL1–READ (OS)

Open the READ breakdown →